Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMC-403 in neovascular age-related macular degeneration
NCT05953012Phase 1Completed
- Sponsor
- PharmAbcine
- Start
- Jul 2023
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of pmc-403 in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by PharmAbcine. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Adverse Events at 5 months and 12 more. Started Jul 2023; status: completed.
02
Drugs
pmc-403
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05953012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05953012.